Current and effective strategies of treatment the acute ischemic stroke with edaravone: a review of the evidence | Український Медичний Часопис

In the adult population, acute ischemic stroke ranks first among various neurological diseases in terms of frequency and disabling effects. The main goal of therapy is not only to prevent the development of recurrent episodes, but also to offset the existing neurological deficit. The article presents the results of new systematic reviews and meta-analyses, data from experimental and clinical studies demonstrating that edaravone has powerful antioxidant properties, its ability to scavenge oxygen free radicals, helping to reduce neuroinflammation, cerebral edema and excessive microglial activation. The ischemic cascade blocker edaravone is used in the complex therapy of cerebrovascular disorders in the acute and subacute periods; its use contributes to the regression of neurological deficits and allows for faster clinical stabilization, accelerated functional recovery, improved prognosis, and reduced risk of death.

References

1. CDC. Stroke Facts. http://www.cdc.gov/stroke/facts.htm.
2. Gallucci L., Sperber C., Guggisberg A. et al. (2024) Post-stroke cognitive impairment remains highly prevalent and disabling despite state-of-the-art stroke treatment. Int. J. Stroke. doi: 10.1177/17474930241238637.
3. GBD 2019 Stroke Collaborators (2021) Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol., 20(10): 795–820. doi: 10.1016/S1474-4422(21)00252-0.
4. Yang X., Sun J., Zhang W. (2024) Global burden of stroke attributable to secondhand smoke in 204 countries and territories from 1990 to 2019: analysis of the global burden of disease study. Front Neurol., 15: 1320033. doi: 10.3389/fneur.2024.1320033.
5. Pu L., Wang L., Zhang R. et al. (2023) Projected Global Trends in Ischemic Stroke Incidence, Deaths and Disability-Adjusted Life Years From 2020 to 2030. Stroke, 54(5): 1330–1339. doi: 10.1161/STROKEAHA.122.040073.
6. Центр громадського здоров’я МОЗ України (2020) Всесвітній день боротьби з інсультом. phc.org.ua/news/29-zhovtnya-vsesvitniy-den-borotbi-z-insultom.
7. МОЗ України (2023) Інсульт: що робить держава для пацієнтів. moz.gov.ua/article/news/insult-scho-robit-derzhava-dlja-pacientiv.
8. Ghozy S., Reda A., Varney J. et al. (2022) Neuroprotection in Acute Ischemic Stroke: A Battle Against the Biology of Nature. Front. Neurol., 13: 870141. doi: 10.3389/fneur.2022.870141.
9. Alexandrov A., Krishnaiah B. (2023) Ischemic Stroke. http://www.msdmanuals.com/professional/neurologic-disorders/stroke/ischemic-stroke.
10. Powers W.J., Rabinstein A.A., Ackerson T. et al. (2018) 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke.
11. Nogueira R.G., Jadhav A.P., Haussen D. (2018) Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N. Engl. J. Med., 378(1): 11–21. doi: 10.1056/NEJMoa1706442.
12. Dammavalam V., Lin S., Nessa S. et al. (2024) Neuroprotection during Thrombectomy for Acute Ischemic Stroke: A Review of Future Therapies. Int. J. Mol. Sci., 25(2): 891. doi: 10.3390/ijms25020891.
13. Miyamoto S., Ogasawara K., Kuroda S. et al. (2022) Japan Stroke Society Guideline 2021 for the Treatment of Stroke. Int. J. Stroke, 17(9): 1039–1049. doi: 10.1177/17474930221090347.
14. Kimura K., Aoki J., Sakamoto Y. et al. (2012) Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients — a preliminary study. J. Neurol. Sci., 313(1–2): 132–136. doi: 10.1016/j.jns.2011.09.006.
15. Chen C., Li M., Lin L. et al. (2021) Clinical effects and safety of edaravone in treatment of acute ischaemic stroke: A meta-analysis of randomized controlled trials. J. Clin. Pharm. Ther., 46(4): 907–917. doi: 10.1111/jcpt.13392.
16. Shakkour Z., Issa H., Ismail H. et al. (2021) Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury. Curr. Med. Chem., 28(12): 2369–2391. doi: 10.2174/0929867327666200812221022.
17. Li X., Yu J., Ma D. et al. (2021) Edaravone Improves the Post-traumatic Brain Injury Dysfunction in Learning and Memory by Modulating Signal Pathway. Clinics (Sao Paulo), 76: e3131. doi: 10.6061/clinics/2021/e3131.
18. Duranti E., Cordani N., Villa C. (2024) Edaravone: A Novel Possible Drug for Cancer Treatment? Int. J. Mol. Sci., 25(3): 1633. doi: 10.3390/ijms25031633.
19. El-Shoura E., Hassanein E., Taha H. et al. Edaravone and obeticholic acid protect against cisplatin-induced heart toxicity by suppressing oxidative stress and inflammation and modulating Nrf2, TLR4/p38MAPK, and JAK1/STAT3/NF-κB signals. Naunyn Schmiedebergs Arch Pharmacol. doi: 10.1007/s00210-024-02956-5.
20. Edaravone Acute Infarction Study Group (2003) Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc. Dis., 15(3): 222–229.
21. Yang J., Cui X., Li J. et al. (2015) Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials. Dev. Neurorehabil., 18(5): 330–335.
22. Miyaji Y., Yoshimura S., Sakai N. et al. (2015) Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan Registry. Neurol. Med. Chir. (Tokyo), 55(3): 241–247.
23. Yamaguchi T., Awano H., Matsuda H. et al. (2017) Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). J. Stroke Cerebrovasc. Dis., 26(4): 756–765.
24. Enomoto M., Endo A., Yatsushige H. et al. (2019) Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy. Stroke, 50(3): 652–658. doi: 10.1161/STROKEAHA.118.023815.
25. Lee T.H., Uchiyama S., Kusuma Y. et al. (2024) A systematic-search-and-review of registered pharmacological therapies investigated to improve neuro-recovery after a stroke. Front. Neurol., 15: 1346177. doi: 10.3389/fneur.2024.1346177.
26. Hu R., Guo Y., Lin Y. et al. (2021) Safety and efficacy of edaravone combined with alteplase for patients with acute ischemic stroke: A systematic review and meta-analysis. Pharmazie, 76(2): 109–113. doi: 10.1691/ph.2021.0949.
27. Zhao K., Li G.Z., Nie L. (2022) Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis. Clin Ther., 44(12): e29–e38. doi: 10.1016/j.clinthera.2022.11.005.
28. Fidalgo M., Ricardo Pires J. et al. (2022) Edaravone for acute ischemic stroke — Systematic review with meta-analysis. Clin. Neurol. Neurosurg., 219: 107299. doi: 10.1016/j.clineuro.2022.107299.
29. Badillo S., Navarro J. (2023) Safety of edaravone in acute ischemic stroke: A systematic review and meta-analysis. Neurology Asia, 28: 39–53. doi: 10.54029/2023pwf.
30. Галушко О.А. (2019) Перший досвід застосування нового поглинача вільних радикалів Ксаврону у хворих на ішемічний інсульт. Медицина невідкладних станів, 3(98): 51–55.
31. Московко С.П., Кириченко Е.В., Руденко Г.С. (2021) Окончательная оценка результатов исследования СТИКс (Сопутственная Терапия Инсульта Ксавроном). Междунар. неврол. журн., 17(5): 92–104.